124 related articles for article (PubMed ID: 21382166)
1. A glycyrrhizin-containing preparation reduces hepatic steatosis induced by hepatitis C virus protein and iron in mice.
Korenaga M; Hidaka I; Nishina S; Sakai A; Shinozaki A; Gondo T; Furutani T; Kawano H; Sakaida I; Hino K
Liver Int; 2011 Apr; 31(4):552-60. PubMed ID: 21382166
[TBL] [Abstract][Full Text] [Related]
2. Stronger Neo-Minophagen C, a glycyrrhizin-containing preparation, protects liver against carbon tetrachloride-induced oxidative stress in transgenic mice expressing the hepatitis C virus polyprotein.
Hidaka I; Hino K; Korenaga M; Gondo T; Nishina S; Ando M; Okuda M; Sakaida I
Liver Int; 2007 Aug; 27(6):845-53. PubMed ID: 17617128
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C virus protein and iron overload induce hepatic steatosis through the unfolded protein response in mice.
Nishina S; Korenaga M; Hidaka I; Shinozaki A; Sakai A; Gondo T; Tabuchi M; Kishi F; Hino K
Liver Int; 2010 May; 30(5):683-92. PubMed ID: 20214734
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription.
Nishina S; Hino K; Korenaga M; Vecchi C; Pietrangelo A; Mizukami Y; Furutani T; Sakai A; Okuda M; Hidaka I; Okita K; Sakaida I
Gastroenterology; 2008 Jan; 134(1):226-38. PubMed ID: 18166355
[TBL] [Abstract][Full Text] [Related]
5. [Effect of decoction of turtle shell for anti-fibrosis combined with stronger neo-minophagen C on indices of hepatic fibrosis in chronic hepatitis B].
Zhang L; Chang Y
Zhongguo Zhong Yao Za Zhi; 2012 Jan; 37(2):258-61. PubMed ID: 22737864
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of intravenous stronger neo-minophagen C and S-adenosyl-L-methionine in treatment of pregnant woman with chronic hepatitis B: a pilot study.
Sun QF; Ding JG; Wang XF; Fu RQ; Yang JX; Hong L; Xu XJ; Wang JR; Wu JG; Xu DZ
Med Sci Monit; 2010 Aug; 16(8):PR9-14. PubMed ID: 20671623
[TBL] [Abstract][Full Text] [Related]
7. Impact of amino acid substitutions in the hepatitis C virus genotype 1b core region on liver steatosis and hepatic oxidative stress in patients with chronic hepatitis C.
Tachi Y; Katano Y; Honda T; Hayashi K; Ishigami M; Itoh A; Hirooka Y; Nakano I; Samejima Y; Goto H
Liver Int; 2010 Apr; 30(4):554-9. PubMed ID: 19951380
[TBL] [Abstract][Full Text] [Related]
8. Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein.
Furutani T; Hino K; Okuda M; Gondo T; Nishina S; Kitase A; Korenaga M; Xiao SY; Weinman SA; Lemon SM; Sakaida I; Okita K
Gastroenterology; 2006 Jun; 130(7):2087-98. PubMed ID: 16762631
[TBL] [Abstract][Full Text] [Related]
9. [Prevention of development of hepatocellular carcinoma from HCV-associated liver cirrhosis by multi-agents therapy including stronger-neo-minophagen C].
Tarao K
Nihon Rinsho; 2001 Oct; 59 Suppl 6():769-73. PubMed ID: 11762054
[No Abstract] [Full Text] [Related]
10. Interferon therapy in hepatitis C virus (HCV) induced chronic hepatitis: clinical significance of pretreatment with glycyrhizine.
Fujisawa K
Trop Gastroenterol; 1991; 12(4):176-9. PubMed ID: 1726032
[No Abstract] [Full Text] [Related]
11. Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARgamma.
Kim KH; Shin HJ; Kim K; Choi HM; Rhee SH; Moon HB; Kim HH; Yang US; Yu DY; Cheong J
Gastroenterology; 2007 May; 132(5):1955-67. PubMed ID: 17484888
[TBL] [Abstract][Full Text] [Related]
12. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis.
Moriya K; Nakagawa K; Santa T; Shintani Y; Fujie H; Miyoshi H; Tsutsumi T; Miyazawa T; Ishibashi K; Horie T; Imai K; Todoroki T; Kimura S; Koike K
Cancer Res; 2001 Jun; 61(11):4365-70. PubMed ID: 11389061
[TBL] [Abstract][Full Text] [Related]
13. [Alternative therapies for hepatitis C: UDCA and SNMC].
Matsuzaki Y; Ikegami T; Saito Y
Nihon Rinsho; 2011 May; 69 Suppl 4():256-61. PubMed ID: 22096928
[No Abstract] [Full Text] [Related]
14. Protective effect and mechanism of stronger neo-minophagen C against fulminant hepatic failure.
Yang BS; Ma YJ; Wang Y; Chen LY; Bi MR; Yan BZ; Bai L; Zhou H; Wang FX
World J Gastroenterol; 2007 Jan; 13(3):462-6. PubMed ID: 17230620
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of liver injury. III. Oxidative stress in the pathogenesis of hepatitis C virus.
Choi J; Ou JH
Am J Physiol Gastrointest Liver Physiol; 2006 May; 290(5):G847-51. PubMed ID: 16603728
[TBL] [Abstract][Full Text] [Related]
16. Hepatic iron, liver steatosis and viral genotypes in patients with chronic hepatitis C.
Sebastiani G; Vario A; Ferrari A; Pistis R; Noventa F; Alberti A
J Viral Hepat; 2006 Mar; 13(3):199-205. PubMed ID: 16475996
[TBL] [Abstract][Full Text] [Related]
17. [Hepatitis C virus-associated and metabolic steatosis. Different or overlapping diseases?].
Lonardo A; Loria P; Adinolfi LE; Andreana A; Ruggiero G; Carulli N
Ann Ital Med Int; 2005; 20(1):10-22. PubMed ID: 15859390
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy and safety of Stronger Neo-Minophagen C for treatment of chronic hepatitis B: a meta-analysis of randomized controlled trials].
Chen J; Wang J; Qin T; Huang Y; Li J
Nan Fang Yi Ke Da Xue Xue Bao; 2014 Jul; 34(8):1224-9. PubMed ID: 25176104
[TBL] [Abstract][Full Text] [Related]
19. The long term efficacy of glycyrrhizin in chronic hepatitis C patients.
Arase Y; Ikeda K; Murashima N; Chayama K; Tsubota A; Koida I; Suzuki Y; Saitoh S; Kobayashi M; Kumada H
Cancer; 1997 Apr; 79(8):1494-500. PubMed ID: 9118029
[TBL] [Abstract][Full Text] [Related]
20. Prolonged ethanol administration depletes mitochondrial DNA in MnSOD-overexpressing transgenic mice, but not in their wild type littermates.
Larosche I; Choumar A; Fromenty B; Lettéron P; Abbey-Toby A; Van Remmen H; Epstein CJ; Richardson A; Feldmann G; Pessayre D; Mansouri A
Toxicol Appl Pharmacol; 2009 Feb; 234(3):326-38. PubMed ID: 19063909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
